Vilain K, Li H, Kwong WJ, et al. - Given that noninferiority of once-daily 60 mg (30 mg dose-reduced) edoxaban vs warfarin for prevention of stroke/systemic embolism in patients suffering from atrial fibrillation was reported in the ENGAGE AF–TIMI 48 trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48), researchers herein investigated the effect of edoxaban vs warfarin on rates of hospitalizations. For this purpose, they used data from ENGAGE AF–TIMI 48 for the 14,024 randomized patients who were treated with at least one dose of study drug. They found that a significantly lower overall rate of cardiovascular- or bleeding-related hospitalization as well as significant decreases in the subcategories of cardiovascular-related, stroke-related, bleed-related, and nonstroke cardiovascular–related hospitalizations were conferred by treatment with edoxaban 60 mg (30 mg dose-reduced) vs warfarin. These data indicate the potential for cost offsets with edoxaban, with even greater decreases in higher-risk patients.